Our Services
Medical Information
Helpful Resources
Published on: 9/12/2026
Severe stomach pain on Mounjaro (tirzepatide) can signal pancreatitis or gallbladder problems such as gallstones or cholecystitis, but it may also stem from common side effects like constipation, gastritis, or delayed stomach emptying. Warning signs that point toward pancreatitis include intense upper abdominal pain that radiates to the back, persistent vomiting, and pain that worsens after eating, while gallbladder pain often centers in the upper right abdomen and may come with fever, yellowing skin, or pain under the right shoulder blade. Rapid weight loss on GLP-1 medications also raises gallstone risk, so timing, pain location, and accompanying symptoms all matter when sorting out the cause. Several important factors separate a serious emergency from a manageable side effect, and the details below explain what to watch for and when to stop the medication and seek urgent care.
Because these conditions overlap and can escalate quickly, the fastest way to understand your own pattern of symptoms is to complete a free, instant, online symptom check that reviews your pain location, severity, and risk factors, then points you toward the right level of care and the questions to raise with your prescriber.
Last reviewed for medical accuracy: 09/12/2026
Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and, in some cases, weight management. Like other medications in its class, it can cause gastrointestinal side effects—most commonly nausea, diarrhea, vomiting and abdominal discomfort. While mild to moderate stomach upset is expected when starting Mounjaro or increasing the dose, severe or persistent abdominal pain warrants extra attention.
Two serious but rare conditions that can cause intense stomach pain are pancreatitis and gallbladder disease. This guide explains:
Pancreatitis is inflammation of the pancreas, the gland behind the stomach that makes digestive enzymes and hormones like insulin. Drug-induced pancreatitis is rare, but some reports link GLP-1 receptor agonists (and by extension Mounjaro) to a small increased risk.
Gallbladder issues, notably gallstones (solid particles forming inside the gallbladder) and cholecystitis (inflammation of the gallbladder), can also present as severe stomach pain. Rapid weight loss—seen with potent appetite-suppressing drugs like Mounjaro—may increase the chance of gallstone formation.
Symptoms can overlap, but certain clues help doctors distinguish the two:
Symptom
| Pancreatitis | Gallbladder Disease
---|---|---
Pain location | Center or left upper abdomen | Right upper abdomen
Radiation | To the back | To right shoulder or back
Onset | Sudden, severe | May be sudden or after heavy meal
Nausea/vomiting | Common, severe | Common
Fever | Possible | Common if infection
Jaundice | Unlikely unless severe | More likely if bile duct obstruction
If you experience severe or prolonged abdominal pain—regardless of exact location—don’t assume it’s “just” a side effect of Mounjaro.
Before you see a provider, you can try a free, online symptom check, using the doctor approved Ubie Symptom Checker to better understand your risks and prepare questions for your appointment. This tool is designed by medical professionals to help you track symptoms and identify when urgent care may be needed.
Always reach out if you experience:
These symptoms can indicate conditions that require prompt medical or even emergency care.
Mounjaro offers significant benefits for blood sugar control and weight loss, but like all medications, it carries potential risks. The chances of gallbladder problems or pancreatitis remain low, especially with appropriate monitoring and lifestyle adjustments.
By staying informed:
You can continue to reap the benefits of Mounjaro while minimizing serious side effects.
Remember: This information is not a substitute for professional medical advice. If you have severe or worrying symptoms, always speak to a doctor promptly about anything that could be life threatening or serious.
(References)
* Mishra R, Raj R, Elshimy G, Zapata I, Kannan L, Majety P, Edem D, Correa R. Adverse Events Related to Tirzepatide. J Endocr Soc. 2023 Feb 9;7(4):bvad016. doi: 10.1210/jendso/bvad016. Epub 2023 Jan 26. PMID: 36789109; PMCID: PMC9915969.
* Zeng Q, Xu J, Mu X, Shi Y, Fan H, Li S. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1214334. doi: 10.3389/fendo.2023.1214334. Epub 2023 Oct 16. PMID: 37908750; PMCID: PMC10613702.
* Caruso I, Di Gioia L, Di Molfetta S, Caporusso M, Cignarelli A, Sorice GP, Laviola L, Giorgino F. The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. J Endocrinol Invest. 2024 Nov;47(11):2671-2678. doi: 10.1007/s40618-024-02441-z. Epub 2024 Aug 14. PMID: 39141075; PMCID: PMC11473560.
* Ghusn W, Hurtado MD. Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks. Obes Pillars. 2024 Dec;12:100127. doi: 10.1016/j.obpill.2024.100127. Epub 2024 Aug 31. PMID: 39286601; PMCID: PMC11404059.
* Jalleh RJ, Marathe CS, Rayner CK, Jones KL, Umapathysivam MM, Wu T, Quast DR, Plummer MP, Nauck MA, Horowitz M. Physiology and Pharmacology of Effects of GLP-1-based Therapies on Gastric, Biliary and Intestinal Motility. Endocrinology. 2024 Nov 26;166(1). doi: 10.1210/endocr/bqae155. PMID: 39568409; PMCID: PMC11630531.
* Mando N, Thomson E, Fowler M, Short L, Gillen N. Acute Pancreatitis Caused by Tirzepatide. Cureus. 2024 Dec;16(12):e76007. doi: 10.7759/cureus.76007. Epub 2024 Dec 19. PMID: 39834977; PMCID: PMC11743417.
* Himmerich H. [Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses?]. Nervenarzt. 2025 May;96(3):247-254. doi: 10.1007/s00115-025-01813-x. Epub 2025 Mar 5. PMID: 40042613; PMCID: PMC12058874.
* Thomsen RW, Mailhac A, Løhde JB, Pottegård A. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes Metab. 2025 Apr;27 Suppl 2(Suppl 2):66-88. doi: 10.1111/dom.16364. Epub 2025 Apr 8. PMID: 40196933; PMCID: PMC12000858.
* Galli M, Benenati S, Laudani C, Simeone B, Sarto G, Ortega-Paz L, Rocco E, Bernardi M, Spadafora L, D'Amario D, Greco E, Frati G, Federici M, Mehran R, Crea F, Angiolillo DJ, Sciarretta S. Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients. J Am Coll Cardiol. 2025 Nov 18;86(20):1805-1819. doi: 10.1016/j.jacc.2025.08.027. Epub 2025 Aug 27. PMID: 40892610.
* Velji-Ibrahim J, Radadiya D, Devani K, Patel H, Nathani P, Hassan C, Pugliese N, Thompson C, Sharma P. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Obesity Management in Adults With and Without Type 2 Diabetes: A Systematic Review. J Obes. 2025;2025:3897161. doi: 10.1155/jobe/3897161. Epub 2025 Oct 19. PMID: 41211586; PMCID: PMC12591819.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.